Press release
TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Download DelveInsight's comprehensive Transforming Growth Factor Beta Inhibitors Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Transforming Growth Factor Beta Inhibitors Pipeline Outlook Report [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Transforming Growth Factor Beta Inhibitors Pipeline Report
* DelveInsight's Transforming Growth Factor Beta Inhibitors pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth Factor Beta Inhibitors treatment.
* The leading Transforming Growth Factor Beta Inhibitors Companies such as Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Promising Transforming Growth Factor Beta Inhibitors Therapies such as Trabedersen, KER-050, STP705 , and others.
Access DelveInsight's in-depth Transforming Growth Factor Beta Inhibitors Pipeline Analysis for a closer look at promising breakthroughs @ Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Emerging Drugs Profile
* Trabedersen: Oncotelic
Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-2 messenger RNA. Ready for registration trials--Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.
* KER-050: Keros Therapeutics
KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF- receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF- family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
* STP705: Sirnaomics
STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.
Get a detailed analysis of the latest innovations in the Transforming Growth Factor Beta Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ Transforming Growth Factor Beta Inhibitors Unmet Needs [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Companies
Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company , and others.
Transforming Growth Factor Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Transforming Growth Factor Beta Inhibitors Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Transforming Growth Factor Beta Inhibitors Therapies and key Transforming Growth Factor Beta Inhibitors Developments @ Transforming Growth Factor Beta Inhibitors Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Transforming Growth Factor Beta Inhibitors Pipeline Report
* Coverage- Global
* Transforming Growth Factor Beta Inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Transforming Growth Factor Beta Inhibitors Therapies- Trabedersen, KER-050, STP705 , and others.
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive Transforming Growth Factor Beta Inhibitors Pipeline Report-access it now! @ Transforming Growth Factor Beta Inhibitors Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Transforming growth factor beta inhibitors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Transforming growth factor beta inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Transforming growth factor beta inhibitors Collaboration Deals
* Late Stage Products (Phase III)
* Trabedersen: Oncotelic
* Mid Stage Products (Phase II)
* KER-050: Keros Therapeutics
* STP705: Sirnaomics
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Transforming growth factor beta inhibitors Key Companies
* Transforming growth factor beta inhibitors Key Products
* Transforming growth factor beta inhibitors- Unmet Needs
* Transforming growth factor beta inhibitors- Market Drivers and Barriers
* Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
* Transforming growth factor beta inhibitors Analyst Views
* Transforming growth factor beta inhibitors Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tgfb-inhibitor-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4165718 • Views: …
More Releases from ABNewswire
Hanley Investment Group Arranges Off-Market Sale of Two Multi-Tenant Retail Pad …
PROVO, Utah - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today the off-market sale of Bulldog Plaza, which comprises two multi-tenant retail pad buildings totaling 13,620 square feet at a CVS-anchored shopping center in Provo, Utah. The property is located at the high-traffic intersection of Cougar Boulevard and University Avenue, adjacent to Brigham Young University (BYU)…
EliteBuilderRenovation Expands Service Line with ADU and Garage Conversion Solut …
Tampa Bay general contractor EliteBuilderRenovation is now offering accessory dwelling unit (ADU) and garage conversion services to help homeowners in Hillsborough, Pinellas and Pasco counties create additional living space, or additional income source and increase property value.
Tampa, FL - October 30, 2025 - EliteBuilderRenovation, a licensed and insured general contracting firm (License #CGC1537676) serving Hillsborough, Pinellas and Pasco counties, has announced the expansion of its service offerings to include accessory…
Firework Unveils AVA 4.0: The AI FAQ Redefining Product Discovery in the Era of …
Powered by Firework's proprietary AI Product Graph and seamlessly integrated within its Agentic Commerce Platform, AVA 4.0 redefines how consumers discover and engage with products online. By transforming static PDPs into conversational shopping experiences, AVA 4.0 enables brands to deliver agentic, personalized interactions that engage, educate, and convert, with 10x faster response times, up to 13.5% conversion rates.
San Mateo, CA - October 30, 2025 - Firework, the world's leading Agentic…
The Boulder Group Arranges Sale of Net Leased Starbucks Property in Illinois
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Starbucks located at 1051 Route 59 in Antioch, Illinois for $2,460,000.
The 2,540 square-foot building benefits from its position along Illinois Route 59 (11,500 VPD) and proximity to Illinois Route 173 (12,900 VPD). The property is neighbored by several nationally recognized retailers that include Jewel-Osco, Ace Hardware, CVS Pharmacy, PNC Bank, and Advance Auto Parts.…
More Releases for Transforming
Transforming Lives , Together
Unessa Foundation is a purpose-driven organization committed to transforming lives, together. Built on the belief that unity and compassion are the cornerstones of meaningful change, Unessa empowers individuals and communities through inclusive programs, collaborative efforts, and a people-first approach.
Rooted in dignity, empathy, and impact, our mission is to uplift underrepresented voices, close opportunity gaps, and strengthen human connections that create lasting social change. At Unessa, we see every person as…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Transforming Higher Education Admissions
Radius X, a user-friendly platform for admission automation and data analysis, is now available for higher education providers. Designed to simplify the admissions process, Radius X enhances the student experience through self-service options and automation.
Admissions teams today face growing challenges as they handle more applications and higher expectations from students. Many are overwhelmed by paperwork and manual tasks that take away valuable time. Radius X addresses these struggles by…
Curiotory: Transforming Language Learning
India's ultimate language learning app
Curiotory is a language learning platform dedicated to creating an enjoyable and effective learning experience. With a focus on online language learning, Curiotory empowers learners to achieve fluency and cultural understanding.
Curiotory, a trailblazer in the language learning industry, is proud to announce its continued commitment to providing a unique, immersive, and personalized approach to language education. With a mission to bridge cultural gaps and make…
Transforming Smiles, Transforming Lives: Introducing Dr. Robert Rifkin, the Maes …
Image: https://www.getnews.info/uploads/3cc5ecdc456666ed434d2b2f5410c024.png
Dr. Robert Rifkin, the visionary force behind some of the most iconic smiles worldwide, continues to redefine the standards of cosmetic dentistry. With over four decades of unparalleled expertise, Dr. Rifkin has earned his place as the godfather of cosmetic dentistry, revolutionizing the field with his innovative treatments and unparalleled artistry.
A Legacy of Innovation
For over 40 years, Dr. Robert Rifkin has been at the forefront of cosmetic dentistry in…
